Historical epidemiology of hepatitis C virus (HCV) in selected countries

P Bruggmann; T Berg; A L H Øvrehus; C Moreno; C E Brandão Mello; F Roudot-Thoraval; R T Marinho; M Sherman; S D Ryder; J Sperl; U Akarca; I Balık; F Bihl; M Bilodeau; A J Blasco; M Buti; F Calinas; J L Calleja; H Cheinquer; P B Christensen; M Clausen; H S M Coelho; M Cornberg; M E Cramp; G J Dore; W Doss; A S Duberg; M H El-Sayed; G Ergör; G Esmat; C Estes; K Falconer; J Félix; M L G Ferraz; P R Ferreira; S Frankova; J García-Samaniego; J Gerstoft; J A Giria; F L Gonçales; E Gower; M Gschwantler; M Guimarães Pessôa; C Hézode; H Hofer; P Husa; R Idilman; M Kåberg; K D E Kaita; A Kautz; S Kaymakoglu; M Krajden; H Krarup; W Laleman; D Lavanchy; P Lázaro; P Marotta; S Mauss; M C Mendes Correa; B Müllhaupt; R P Myers; F Negro; V Nemecek; N Örmeci; J Parkes; K M Peltekian; A Ramji; H Razavi; N Reis; S K Roberts; W M Rosenberg; R Sarmento-Castro; C Sarrazin; D Semela; G E Shiha; W Sievert; P Stärkel; R E Stauber; A J Thompson; P Urbanek; I van Thiel; H Van Vlierberghe; D Vandijck; W Vogel; I Waked; H Wedemeyer; N Weis; J Wiegand; A Yosry; A Zekry; P Van Damme; S Aleman; S J Hindman

doi:10.1111/jvh.12247

Historical epidemiology of hepatitis C virus (HCV) in selected countries

P Bruggmann, T Berg, A L H Øvrehus, C Moreno, C E Brandão Mello, F Roudot-Thoraval, R T Marinho, M Sherman, S D Ryder, J Sperl, U Akarca, I Balık, F Bihl, M Bilodeau, A J Blasco, M Buti, F Calinas, J L Calleja, H Cheinquer, P B ChristensenM Clausen, H S M Coelho, M Cornberg, M E Cramp, G J Dore, W Doss, A S Duberg, M H El-Sayed, G Ergör, G Esmat, C Estes, K Falconer, J Félix, M L G Ferraz, P R Ferreira, S Frankova, J García-Samaniego, J Gerstoft, J A Giria, F L Gonçales, E Gower, M Gschwantler, M Guimarães Pessôa, C Hézode, H Hofer, P Husa, R Idilman, M Kåberg, K D E Kaita, A Kautz, S Kaymakoglu, M Krajden, H Krarup, W Laleman, D Lavanchy, P Lázaro, P Marotta, S Mauss, M C Mendes Correa, B Müllhaupt, R P Myers, F Negro, V Nemecek, N Örmeci, J Parkes, K M Peltekian, A Ramji, H Razavi, N Reis, S K Roberts, W M Rosenberg, R Sarmento-Castro, C Sarrazin, D Semela, G E Shiha, W Sievert, P Stärkel, R E Stauber, A J Thompson, P Urbanek, I van Thiel, H Van Vlierberghe, D Vandijck, W Vogel, I Waked, H Wedemeyer, N Weis, J Wiegand, A Yosry, A Zekry, P Van Damme, S Aleman, S J Hindman

Institut for Klinisk Medicin

200 Citationer (Scopus)

Abstract

Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6,358,000 cases in 2008 and Brazil with 2,106,000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level.

Originalsprog	Engelsk
Tidsskrift	Journal of Viral Hepatitis
Vol/bind	21 S
Udgave nummer	s1
Sider (fra-til)	5-33
Antal sider	29
ISSN	1352-0504
DOI	https://doi.org/10.1111/jvh.12247
Status	Udgivet - 1 maj 2014

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1111/jvh.12247

Citationsformater

Bruggmann, P., Berg, T., Øvrehus, A. L. H., Moreno, C., Brandão Mello, C. E., Roudot-Thoraval, F., Marinho, R. T., Sherman, M., Ryder, S. D., Sperl, J., Akarca, U., Balık, I., Bihl, F., Bilodeau, M., Blasco, A. J., Buti, M., Calinas, F., Calleja, J. L., Cheinquer, H., ... Hindman, S. J. (2014). Historical epidemiology of hepatitis C virus (HCV) in selected countries. Journal of Viral Hepatitis, 21 S(s1), 5-33. https://doi.org/10.1111/jvh.12247

Bruggmann, P, Berg, T, Øvrehus, ALH, Moreno, C, Brandão Mello, CE, Roudot-Thoraval, F, Marinho, RT, Sherman, M, Ryder, SD, Sperl, J, Akarca, U, Balık, I, Bihl, F, Bilodeau, M, Blasco, AJ, Buti, M, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hézode, C, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marotta, P, Mauss, S, Mendes Correa, MC, Müllhaupt, B, Myers, RP, Negro, F, Nemecek, V, Örmeci, N, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Rosenberg, WM, Sarmento-Castro, R, Sarrazin, C, Semela, D, Shiha, GE, Sievert, W, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Vogel, W, Waked, I, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Van Damme, P, Aleman, S & Hindman, SJ 2014, 'Historical epidemiology of hepatitis C virus (HCV) in selected countries', Journal of Viral Hepatitis, bind 21 S, nr. s1, s. 5-33. https://doi.org/10.1111/jvh.12247

@article{c7e952b1dcee49f0b88271d19fa834ad,

title = "Historical epidemiology of hepatitis C virus (HCV) in selected countries",

abstract = "Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6,358,000 cases in 2008 and Brazil with 2,106,000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level.",

keywords = "Antiviral Agents, Global Health, Hepatitis C, Chronic, Humans, Incidence, Liver Transplantation, Prevalence, Survival Analysis",

author = "P Bruggmann and T Berg and {\O}vrehus, {A L H} and C Moreno and {Brand{\~a}o Mello}, {C E} and F Roudot-Thoraval and Marinho, {R T} and M Sherman and Ryder, {S D} and J Sperl and U Akarca and I Balık and F Bihl and M Bilodeau and Blasco, {A J} and M Buti and F Calinas and Calleja, {J L} and H Cheinquer and Christensen, {P B} and M Clausen and Coelho, {H S M} and M Cornberg and Cramp, {M E} and Dore, {G J} and W Doss and Duberg, {A S} and El-Sayed, {M H} and G Erg{\"o}r and G Esmat and C Estes and K Falconer and J F{\'e}lix and Ferraz, {M L G} and Ferreira, {P R} and S Frankova and J Garc{\'i}a-Samaniego and J Gerstoft and Giria, {J A} and Gon{\c c}ales, {F L} and E Gower and M Gschwantler and {Guimar{\~a}es Pess{\^o}a}, M and C H{\'e}zode and H Hofer and P Husa and R Idilman and M K{\aa}berg and Kaita, {K D E} and A Kautz and S Kaymakoglu and M Krajden and H Krarup and W Laleman and D Lavanchy and P L{\'a}zaro and P Marotta and S Mauss and {Mendes Correa}, {M C} and B M{\"u}llhaupt and Myers, {R P} and F Negro and V Nemecek and N {\"O}rmeci and J Parkes and Peltekian, {K M} and A Ramji and H Razavi and N Reis and Roberts, {S K} and Rosenberg, {W M} and R Sarmento-Castro and C Sarrazin and D Semela and Shiha, {G E} and W Sievert and P St{\"a}rkel and Stauber, {R E} and Thompson, {A J} and P Urbanek and {van Thiel}, I and {Van Vlierberghe}, H and D Vandijck and W Vogel and I Waked and H Wedemeyer and N Weis and J Wiegand and A Yosry and A Zekry and {Van Damme}, P and S Aleman and Hindman, {S J}",

note = "{\textcopyright} 2014 John Wiley & Sons Ltd.",

year = "2014",

month = may,

day = "1",

doi = "10.1111/jvh.12247",

language = "English",

volume = "21 S",

pages = "5--33",

journal = "Journal of Viral Hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell",

number = "s1",

}

TY - JOUR

T1 - Historical epidemiology of hepatitis C virus (HCV) in selected countries

AU - Bruggmann, P

AU - Berg, T

AU - Øvrehus, A L H

AU - Moreno, C

AU - Brandão Mello, C E

AU - Roudot-Thoraval, F

AU - Marinho, R T

AU - Sherman, M

AU - Ryder, S D

AU - Sperl, J

AU - Akarca, U

AU - Balık, I

AU - Bihl, F

AU - Bilodeau, M

AU - Blasco, A J

AU - Buti, M

AU - Calinas, F

AU - Calleja, J L

AU - Cheinquer, H

AU - Christensen, P B

AU - Clausen, M

AU - Coelho, H S M

AU - Cornberg, M

AU - Cramp, M E

AU - Dore, G J

AU - Doss, W

AU - Duberg, A S

AU - El-Sayed, M H

AU - Ergör, G

AU - Esmat, G

AU - Estes, C

AU - Falconer, K

AU - Félix, J

AU - Ferraz, M L G

AU - Ferreira, P R

AU - Frankova, S

AU - García-Samaniego, J

AU - Gerstoft, J

AU - Giria, J A

AU - Gonçales, F L

AU - Gower, E

AU - Gschwantler, M

AU - Guimarães Pessôa, M

AU - Hézode, C

AU - Hofer, H

AU - Husa, P

AU - Idilman, R

AU - Kåberg, M

AU - Kaita, K D E

AU - Kautz, A

AU - Kaymakoglu, S

AU - Krajden, M

AU - Krarup, H

AU - Laleman, W

AU - Lavanchy, D

AU - Lázaro, P

AU - Marotta, P

AU - Mauss, S

AU - Mendes Correa, M C

AU - Müllhaupt, B

AU - Myers, R P

AU - Negro, F

AU - Nemecek, V

AU - Örmeci, N

AU - Parkes, J

AU - Peltekian, K M

AU - Ramji, A

AU - Razavi, H

AU - Reis, N

AU - Roberts, S K

AU - Rosenberg, W M

AU - Sarmento-Castro, R

AU - Sarrazin, C

AU - Semela, D

AU - Shiha, G E

AU - Sievert, W

AU - Stärkel, P

AU - Stauber, R E

AU - Thompson, A J

AU - Urbanek, P

AU - van Thiel, I

AU - Van Vlierberghe, H

AU - Vandijck, D

AU - Vogel, W

AU - Waked, I

AU - Wedemeyer, H

AU - Weis, N

AU - Wiegand, J

AU - Yosry, A

AU - Zekry, A

AU - Van Damme, P

AU - Aleman, S

AU - Hindman, S J

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6,358,000 cases in 2008 and Brazil with 2,106,000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level.

AB - Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6,358,000 cases in 2008 and Brazil with 2,106,000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level.

KW - Antiviral Agents

KW - Global Health

KW - Hepatitis C, Chronic

KW - Humans

KW - Incidence

KW - Liver Transplantation

KW - Prevalence

KW - Survival Analysis

U2 - 10.1111/jvh.12247

DO - 10.1111/jvh.12247

M3 - Journal article

C2 - 24713004

SN - 1352-0504

VL - 21 S

SP - 5

EP - 33

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

IS - s1

ER -

Historical epidemiology of hepatitis C virus (HCV) in selected countries

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater